Stock screener

NAMS

Conviction 20HealthcareScan · Tue, Sep 8, 2026
Bullish engulfing
NAMS$25.66+1.02%
ResistanceSupportVol 14Insider sell
63 bars
2
Vol MA14 1.14M
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
NewAmsterdam Pharma Co N.V.PHARMACEUTICAL PREPARATIONSwww.newamsterdampharma.com ↗
Price25.66
Change+1.02%
Gap-5.04%
Rel volume3.32×
Avg volume1.19M
Avg $ vol31.85M
SMA 2026.72
SMA 5029.49
SMA 20032.49
Price vs 50-13.00%
Price vs 200-21.03%
MA stackbearish
50/200 cross—
Supertrenddown · 28.43
RSI (14)39
MACD hist0.00
MACD crossbull · 0d
Stoch %K / %D44 / 28
ADX (14)38
+DI / −DI9 / 32
RSI divergence—
MACD divergence—
ATR %+4.97%
ADR %4.08%
52w high41.45
52w low24.12
From 52w high-38.09%
Above 52w low+6.38%
New 52w highNo
SqueezeOn · 1d
Bollinger width14.87%
%B0.23
Donchian pos43.74%
Donchian high28.76
Donchian low23.25
AVWAP (52w high)31.26
vs AVWAP high-17.91%
AVWAP (52w low)32.94
vs AVWAP low-22.10%
OBV trendFlat
Chaikin MF (20)-0.02
Today vs 20d3.32×
Avg vol (14d)1.14M
Avg vol (20d)1.19M
Avg $ vol (20d)31.85M
Market cap3.07B
RS 3m (vs SPY)-23.84%
RS 6m (vs SPY)-29.48%
RS line new highNo
Trend template0/8
Technical rank15.0
1 week+1.26%
1 month-8.23%
3 months-17.09%
6 months-16.61%
1 year-4.96%
YTD-27.10%
P/E-15.05
P/B4.86
P/S136.31
P/FCF-20.72
EPS-1.72
Div yield—
ROE-32.28%
ROA-28.93%
Debt/Eq—
Current9.03
EV/EBITDA-11.72
Gross margin—
Net margin-905.74%
Rev growth-50.61%
EPS growth15.64%
Price target53.29
Target upside107.68%
Analyst ratingBuy
Institutional104.26%
Ent. value2.64B
Revenue3.7M
Net income-64.14M
Gross profit—
Free cash flow-148.03M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out116.9M
Employees100
ListedWed, Nov 23, 2022
Free float62.23M
Float %53.2%
Short interest12.65M
Days to cover9.9d
Short volume51.3%
Squeeze score88 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.52 vs −$0.48
Last surprise-8.3% miss
Setup gradeD
Conviction20 / 100
Pattern quality—
Tech rank15.0 / 100
Group rank96 / 100 · Leading
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmBullish engulfing
News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in NAMS

All disclosures →
No recent disclosed trades by Congress in NAMS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in NAMS · 5 buys · 5 sells

InsiderSideShares
Kastelein Johannes Jacob Pieter
Chief Scientific Officer · Ordinary Shares · 2026-08-24
Exercise125K
Kastelein Johannes Jacob Pieter
Chief Scientific Officer · Ordinary Shares · 2026-08-24
Sell125K
Kastelein Johannes Jacob Pieter
Chief Scientific Officer · Option (right to buy) · 2026-08-24
Exercise125K
Kooij Louise Frederika
Chief Accounting Officer · Ordinary Shares · 2026-07-20
Sell70.2K
Kooij Louise Frederika
Chief Accounting Officer · Ordinary Shares · 2026-07-20
Sell31.89K
Kooij Louise Frederika
Chief Accounting Officer · Ordinary Shares · 2026-07-20
Exercise25K
Kooij Louise Frederika
Chief Accounting Officer · Ordinary Shares · 2026-07-20
Exercise80K
Kooij Louise Frederika
Chief Accounting Officer · Option (right to buy) · 2026-05-26
Exercise5K
Kooij Louise Frederika
Chief Accounting Officer · Ordinary Shares · 2026-05-26
Exercise5K
Kooij Louise Frederika
Chief Accounting Officer · Ordinary Shares · 2026-05-26
Exercise60K

SEC filings

EDGAR filings in NAMS · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.